Have any questions? 706-721-6582 or cts@augusta.edu
- Global Cardio Oncology Registry
Clinical Trial
Global Cardio Oncology Registry
Cardio-oncology addresses the increased CVD risk in cancer survivors due to improved cancer therapy. Common treatments can cause cancer treatment-related cardiovascular disease (CTRCD), but early detection and monitoring protect cardiovascular health. Limited data exist on recommended practices and the impact of CTRCD in different settings and populations. The lack of validated risk stratification and treatment approaches for cancer therapy-related cardiac dysfunction hinders effective screening and treatment. The Global Cardio-Oncology Registry (G-COR) aims to gather data from diverse cardio-oncology patients worldwide to establish CTRCD incidence, identify risk factors, and understand socioeconomic and demographic impacts on care and outcomes. This multinational collaboration seeks to build a comprehensive database and platform for future studies and clinical trials. Objectives: Determine CTRCD incidence in participating centres. Identify and validate risk factors and score models for CTRCD. Assess geographic differences in biomarker and imaging utilization and their impact on CTRCD management. Examine the impact of socioeconomic and demographic factors on access to care, surveillance, treatments, and outcomes. Evaluate outcomes of cancer survivors treated with various cardio-toxic modalities across different locations. Establish a platform for collaborations, sub-studies, and prospective clinical research.
Eligibility Criteria
- Inclusion Criteria: 1. Patients that are 18 years of age and older. 2. Patients with the following cancer diagnosis (three main pillars): a. Breast cancer b. Hematological malignancies (lymphomas, leukemia, multiple myeloma) c. Patients treated with immune check point inhibitors Only patients referred to cardio-oncology services due to cardiovascular symptoms, abnormal test results or presence of pre-existing cardiovascular disease and/or CV risk factors will be included. 3. Enrollment can occur before, during or after cancer treatment. 4. Patients are willing to follow up at the enrolling center. Exclusion Criteria: 1. Unwillingness to provide written informed consent or waiver of consent depending on institutional requirements. 2. Patients will not be following up at the participating site. 3. Patients that at initial medical evaluation are classified as with low cardiovascular risk or presenting cardiovascular toxicity.